Telavancin: A novel lipoglycopeptide antibiotic

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 928-938

  Charneski, Lisa ^a,d   Patel, Priti N ^b   Sym, Donna ^b,c  

^a University of Maryland Shady Grove Campus   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d Building 1 ^*  (United States)

Author keywords

Skin and skin structure infection; TD 6424; Telavancin

Indexed keywords

ANTIBIOTIC AGENT; CLOXACILLIN; NAFCILLIN; TELAVANCIN; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFORMATION; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HYPOKALEMIA; INSOMNIA; MEDICAL LITERATURE; MENTAL DISEASE; MICROALBUMINURIA; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; TASTE DISORDER; THROMBOCYTE COUNT; VOMITING;

AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MODELS, MOLECULAR; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 65749083291     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G417     Document Type: Article

References (51)

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46:S344-9.
2. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD -6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004;48:3043-3050
3. Centers for Disease Control and Prevention. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections- Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003;52:88.
4. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol 2004;4:471-478 (Pubitemid 40533007)
5. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543-1548
6. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin- resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402
7. Hidayat LK, Hsu DI, Quist Ryan, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-2144
8. Doern GV, Richter SS, Miller, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005;41:139-148
9. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD -6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 2004;53:797-803. (Pubitemid 38660281)
10. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial- resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
11. Theravance announces fast track designation for investigational antibiotic telavancin. http://ir.theravance.com/releasedetail.cfm?releaseid= 158679 (accessed 2005 Jun 15).
12. US National Institutes of Health. ClinicalTrials.gov. Information on clinical trials and human research studies funded by Theravance. http:// clinicaltrials. gov/ct2/results?term=telavancin (accessed 2008 Jun 18).
13. Theravance reports favorable outcome of FDA advisory committee meeting on telavancin for the treatment of complicated skin and skin structure infections. http://ir.theravance.com/ReleaseDetail.cfm?ReleaseID= 348983 (accessed 2008 Nov 24).
14. Meeting of the Anti-Infective Drugs Advisory Committee. US Food and Drug Administration. www.fda.gov/cder/audiences/acspage/meetings/ antiinfective-november2008-meetings.htm. (accessed 2008 Nov 24).
15. Leonard SN, Ryback MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 2008;28:458-468
16. Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 2007;64:2335-2348 (Pubitemid 350174705)
17. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49:195-201. (Pubitemid 40065793)
18. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide nonsusceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:338-343 (Pubitemid 44294945)
19. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127-1134 (Pubitemid 40327734)
20. Gotfried M, Shaw J, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in health subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008;52:92-97
21. Wong SL, Barriere SL, Kitt MM, et al. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008;62:780-783
22. Duchin K, Shaw J, Spencer E, et al. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004.
23. Duchin K, Shaw J, Spencer E, et al. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004.
24. Wong SL, Shaw JP, Barriere S, et al. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Franscisco, CA, September 17-20, 2006.
25. Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin pinto human epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008;52:2300-2304
26. Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006;50:788-790 (Pubitemid 43191003)
27. Pace JL, Krause K, Johnston D, et al. In vitro activity of TD -6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3602-3604
28. Odenholt I, Löwdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother 2007;51:3311-3316
29. Stucki A, Gerber P, Acosta F, et al. Efficacy of telavancin against penicillin- resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006;50:770-773
30. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of the new semisynthetic glycopeptide telavancin (TD -6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004;48:2149-2152 (Pubitemid 38691612)
31. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm D. Comparative surveillance study of telavancin activity against recent gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52:2383-2388
32. Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008;52:2647-2652
33. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. In vitro activity of telavancin against recent gram-positive clinical isolates: results of the 2004-2005 prospective European surveillance initiative. J Antimicrob Chemother 2008;62:116-121
34. Barcia-Macay M, Lemaire S, Mingeot-Leclercq M, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:1177-1184
35. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005;56:337-343 (Pubitemid 41158522)
36. Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD -6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:4344-4346 (Pubitemid 41400983)
37. Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2007;60:406-409 (Pubitemid 47243894)
38. Center for Drug Evaluation and Research. Uncomplicated and complicated skin and skin structure infections- developing antimicrobial drugs for treatment: guidance for industry. Rockville, MD: US Food and Drug Administration, 1998. www.fda.gov/cder/guidance/2566dft.pdf (accessed 2005 Jul 12).
39. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14:244-269 (Pubitemid 32294670)
40. Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis 1995;20:S283-8.
41. Reyzelman AM, Lipsky BA, Hadi SA, et al. The increased prevalence of severe necrotizing infections caused by non-group A streptococci. J Am Podiatr Med Assoc 1999;89:454-457
42. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-1607
43. Stryjewski ME, Chu VH, O'Riordan WD, et al., Fast2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-867 (Pubitemid 43327787)
44. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683-1693
45. Wilson SE, O'Riordan W, Hopkins A, et al. Televancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 2008 (in press).
46. Rubenstein E, Corey GR, Stryjewski ME, et al. Telavancin for the treatment of hospital-acquired pneumonia (HAP) caused by MRSA and MSSA. The ATTAIN studies. Presented at: 48th ICAAC/IDSA 46th Annual Meeting, a joint meeting of ASM and IDSA, Washington, DC, October 2008.
47. Rubenstein E, Corey GR, Boucher HW, et al. Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients. The ATTAIN studies. Pesented at: 48th ICAAC/IDSA 46th Annual Meeting, a joint meeting of ASM and IDSA. Washington, DC, October 2008.
48. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004;44:689-695 (Pubitemid 38765930)
49. Theravance announces results from clinical and pre-clinical studies with investigational antibiotic telavancin. South San Francisco, CA. http:// ir.theravance.com/releasedetail.cfm?releaseid=159800 (accessed 2005 Jun 15).
50. Hegde SS, Skinner R, Difuntorum S, Krause KM. Efficacy of telavancin against hVISA infection in the neutropenic murine bacteremia model (poster). Presented at: 2008 ICAAC / IDSA conference. A joint meeting of ASM and IDSA. October 2008, Washington DC.
51. Laohaveleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy 2008;28:1471-1482